Health Alert: Chagas Disease, Also Known as American Trypanosomiasis, Poses Life-Threatening Risk from Trypanosoma Cruzi Parasite: BCC Research LLC
Health Alert: Chagas Disease, Also Known as American Trypanosomiasis, Poses Life-Threatening Risk from ... PR Newswire
sdgtalks
Chagas Disease: American Trypanosomiasis Market
Introduction
Chagas disease, also known as American trypanosomiasis, is caused by a small parasite called Trypanosoma cruzi. It was discovered by Dr. Carlos RJ Chagas from Brazil in 1909.
Market Overview
BOSTON, April 16, 2024 /PRNewswire/ — The new research provides a comprehensive analysis of the Chagas Disease: American trypanosomiasis market. The report examines market trends, prevalence in different regions, and current market dynamics. It also focuses on the competition among different treatments, with a particular emphasis on treatments available in Latin America. However, due to limited demand for these products caused by financial constraints among Chagas Disease patients, pharmaceutical companies are not investing significantly in the development of new treatments for the disease.
Key Facts about Chagas Disease
- About 6-7 million people, mostly in Latin America, are affected by Chagas disease.
- The disease can be transmitted through bug bites, consumption of contaminated food or drinks, blood transfusions or organ transplants from infected individuals, mother-to-child transmission, or accidents in laboratories.
- Early treatment can cure Chagas disease and prevent transmission from mother to baby.
- Long-term Chagas disease can lead to heart, stomach, or brain problems that require specialized treatment.
- Prevention measures include bug control, screening blood donors, and testing and treating at-risk individuals.
Transmission of Chagas Disease
In Latin America, Chagas disease is primarily transmitted through the feces or urine of blood-sucking bugs known as kissing bugs. These bugs hide in cracks in houses and feed on blood at night. Scratching the bug bite can introduce the parasite into the body, leading to infection. The disease can also be transmitted through the consumption of contaminated food or drinks, mother-to-child transmission, or blood transfusions.
Signs and Symptoms
Chagas disease has two phases. In the first phase, which lasts about 2 months, most people do not experience any symptoms or only have mild symptoms such as fever, headache, or muscle pain. In the second phase, the parasites hide in the heart and stomach muscles, leading to long-term complications such as heart problems, stomach issues, nerve damage, and even death.
Treatment and Control
Chagas disease can be treated with medications like benznidazole or nifurtimox to kill the parasite. Early treatment is crucial for better outcomes. However, these medications may have side effects and are not recommended for pregnant women or individuals with certain health conditions. Additional treatment may be required to manage complications caused by the disease. Prevention measures include bug control, hygiene practices, and screening of blood and organ donors.
Key Companies in the Chagas Disease Market
- Bayer AG: A multinational pharmaceutical company committed to global health initiatives, including research and development of treatments for neglected tropical diseases like Chagas Disease.
- Sanofi S.A.: A leading pharmaceutical company focusing on innovative treatments for various diseases, including neglected tropical diseases such as Chagas Disease.
- GlaxoSmithKline plc: A global healthcare company dedicated to developing vaccines and treatments for infectious diseases, including Chagas Disease.
- Novartis AG: A pharmaceutical company known for its research and development efforts in addressing unmet medical needs, including therapies for neglected tropical diseases like Chagas Disease.
- Merck & Co., Inc.: A leading global healthcare company committed to developing innovative treatments and vaccines for a wide range of diseases, including Chagas Disease.
For further information or to purchase the report, please contact [email protected].
About BCC Research
BCC Research provides objective, unbiased market research reports to help businesses make informed decisions. Our experienced industry analysts focus on delivering accurate insights without any bias or hype.
Contact Us
Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA
Email: [email protected]
Phone: +1 781-489-7301
For media inquiries, email [email protected] or visit our media page for access to our market research library.
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
SOURCE BCC Research LLC
SDGs, Targets, and Indicators
1. Which SDGs are addressed or connected to the issues highlighted in the article?
- SDG 3: Good Health and Well-being
- SDG 10: Reduced Inequalities
- SDG 17: Partnerships for the Goals
The article discusses Chagas disease, a bug-borne illness prevalent in Latin America. The focus on preventing and treating the disease aligns with SDG 3, which aims to ensure healthy lives and promote well-being for all at all ages. Additionally, the mention of limited access to medicine due to financial constraints highlights the issue of inequality (SDG 10). Lastly, the involvement of pharmaceutical companies and the need for partnerships to address the lack of treatment options relates to SDG 17.
2. What specific targets under those SDGs can be identified based on the article’s content?
- Target 3.3: By 2030, end the epidemics of AIDS, tuberculosis, malaria, and neglected tropical diseases and combat hepatitis, water-borne diseases, and other communicable diseases.
- Target 10.2: By 2030, empower and promote the social, economic, and political inclusion of all, irrespective of age, sex, disability, race, ethnicity, origin, religion, or economic or other status.
- Target 17.16: Enhance the global partnership for sustainable development, complemented by multi-stakeholder partnerships that mobilize and share knowledge, expertise, technology, and financial resources.
The article’s content supports Target 3.3 by addressing Chagas disease as a neglected tropical disease and discussing the need for treatment options. Target 10.2 is relevant as the article mentions the financial constraints faced by individuals with Chagas disease, highlighting the need for inclusion and reducing inequalities in access to healthcare. Lastly, Target 17.16 is relevant as it emphasizes the importance of partnerships between pharmaceutical companies, governments, and organizations to address the lack of treatment options for Chagas disease.
3. Are there any indicators mentioned or implied in the article that can be used to measure progress towards the identified targets?
Yes, the following indicators can be used to measure progress towards the identified targets:
- Indicator 3.3.1: Number of new cases of selected communicable diseases per 100,000 population.
- Indicator 10.2.1: Proportion of people living below 50 percent of median income, by age, sex, and disability.
- Indicator 17.16.1: Number of countries that have national sustainable development strategies, as well as sectoral and local plans, integrated into national development plans.
The article mentions the number of people affected by Chagas disease in Latin America, which can be used as an indicator for measuring progress towards Indicator 3.3.1. The mention of financial constraints faced by individuals with Chagas disease can be used to measure progress towards Indicator 10.2.1. Lastly, the need for partnerships between pharmaceutical companies, governments, and organizations can be used to measure progress towards Indicator 17.16.1.
4. Table: SDGs, Targets, and Indicators
| SDGs | Targets | Indicators |
|---|---|---|
| SDG 3: Good Health and Well-being | Target 3.3: By 2030, end the epidemics of AIDS, tuberculosis, malaria, and neglected tropical diseases and combat hepatitis, water-borne diseases, and other communicable diseases. | Indicator 3.3.1: Number of new cases of selected communicable diseases per 100,000 population. |
| SDG 10: Reduced Inequalities | Target 10.2: By 2030, empower and promote the social, economic, and political inclusion of all, irrespective of age, sex, disability, race, ethnicity, origin, religion, or economic or other status. | Indicator 10.2.1: Proportion of people living below 50 percent of median income, by age, sex, and disability. |
| SDG 17: Partnerships for the Goals | Target 17.16: Enhance the global partnership for sustainable development, complemented by multi-stakeholder partnerships that mobilize and share knowledge, expertise, technology, and financial resources. | Indicator 17.16.1: Number of countries that have national sustainable development strategies, as well as sectoral and local plans, integrated into national development plans. |
Behold! This splendid article springs forth from the wellspring of knowledge, shaped by a wondrous proprietary AI technology that delved into a vast ocean of data, illuminating the path towards the Sustainable Development Goals. Remember that all rights are reserved by SDG Investors LLC, empowering us to champion progress together.
Source: prnewswire.com
Join us, as fellow seekers of change, on a transformative journey at https://sdgtalks.ai/welcome, where you can become a member and actively contribute to shaping a brighter future.
